The Bristol-Myers Squibb Phenomenon: A Game Changer In The Pharmaceutical IndustrySeeking Alpha • 07/21/23
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC MelanomaBusiness Wire • 07/21/23
Bristol Myers Squibb (BMY) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 07/20/23
Bristol Myers Squibb (BMY) Flat As Market Gains: What You Should KnowZacks Investment Research • 07/13/23
Bristol Myers (BMY) Reports Positive Data From Urothelial Cancer StudyZacks Investment Research • 07/12/23
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 TrialBusiness Wire • 07/11/23
Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience PartnershipAccesswire • 07/11/23